Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A812885051

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

About this item

Full title

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Publisher

NewsRX LLC

Journal title

Mental Health Weekly Digest, 2024, p.51

Language

English

Formats

Reports

Publication information

Publisher

NewsRX LLC

Subjects

Subjects and topics

More information

Alternative Titles

Full title

Sage Therapeutics Announces Topline Results from the Phase 2 LIGHTWAVE Study of Dalzanemdor SAGE-718 in the Treatment of Mild Cognitive Impairment and Mild Dementia in Alzheimer's Disease

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_gale_infotracmisc_A812885051

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_gale_infotracmisc_A812885051

Other Identifiers

ISSN

1543-6616

How to access this item

Log in as a Library member

View record in Gale

View in old catalogue

Connecting people and collections

Indigenous engagement

Celebrating and sharing stories of Indigenous Australia, and helping to locate and prioritise Indigenous voices in the Library's collections.

Schools and teachers

Learning programs and resources linked to the curriculum.

Stories

Showcasing people, places and ideas inspired by the collection and the library community.